⌕
Halozyme Therapeutics · HALO · Nasdaq
Tenet 71 · Solid
Compare
$95.97−0.55%At closeTenet 71 · Solid
$95.97−0.53 (−0.55%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Halozyme Therapeutics (HALO) Earnings Forecast

Analysts expect Halozyme Therapeutics (HALO) to earn $8.66 a share in FY26, the average of 5 estimates as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY26 consensus EPS
$8.66
5 analysts
FY27 consensus EPS
$10.34
4 analysts · low $9.51, high $11.39
EPS revisions, 31 days
+0.5%
$8.61 to $8.66
Disagreement, FY26
2.9%
high to low, $8.54 to $8.79

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Halozyme Therapeutics to earn $9.91 a share in FY30, growing about 3% a year; 1 analyst publishes an estimate for FY30.

Forward P/E · FY26E
11.1×
$96.50 (as of close, Nov 16, 2026) ÷ $8.66 consensus EPS
Coverage · FY26
5 · 6
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $8.66, up 9.0% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−1.6%+4.5%+10.6%FY26 +9.0%FY27 +3.7%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY265 analysts▲ +0.5%$8.61 to $8.66▲ +9.0%$7.94 to $8.66▲ +6.8%$8.11 to $8.66
FY274 analysts▼ −0.7%$10.41 to $10.34▲ +3.7%$9.97 to $10.34▲ +4.1%$9.93 to $10.34
Dec '264 analysts▲ +0.4%$2.56 to $2.57▲ +3.0%$2.49 to $2.57▲ +3.0%$2.49 to $2.57
Mar '272 analysts24 of 30 days0.0% so far24 of 90 days0.0% so far◆ 0.0%$2.24 to $2.24

Contributors at both ends of the window: FY26 5 and 5. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

At 24.4 times earnings, which is what Halozyme Therapeutics trades at today, the FY27 consensus of $10.34 works out to $252 a share.

Consensus EPS · FY27
$10.34
4 analysts · low $9.51, high $11.39 · thin coverage
Multiple · today's trailing P/E
24.4×
$96.50 (as of close, Nov 16, 2026) ÷ $3.96, the last four reported quarters, including EPS computed by Tenet
×
Receipt · HALO · FY27Nov 16, 2026
Implied, a share
$252

Range on the low and high estimate: $232 to $278.

$232 low$278 high
10.34 × 24.4, to the dollar
Drag the multipleShaded: where Halozyme Therapeutics' P/E sat at each fiscal year end, FY17 to FY25. Each dot is one year.
12×20×30×40×50×
5-yr avg 22.4×today 24.4×10-yr median 26.3×$252 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 11.1 times the FY26 consensus for earnings the Street expects to grow about 18% a year to FY28. That is 0.6 times the growth rate.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY17 to FY25 · over 7 fiscal years. The mark is the median of the last 7.
24.4× today
13.9× low46.8× high
26.3× median
Forward 11.1× is a different measure, so it is not placed on a trailing record. Today's mark is the trailing 24.4×, on the same basis as every year behind it.

How much do analysts disagree?

For FY30, estimates run from $9.42 to $10.44 around an average of $9.91, drawn by 1 analyst.

FY26E5 analysts
$8.54 to $8.79 · 2.9%
FY27E4 analysts
$9.51 to $11.39 · 18.2%
FY28E3 analysts
$11.86 to $12.10 · 2.0%
FY29E1 analyst
$10.14 to $11.24 · 10.3%
FY30E1 analyst
$9.42 to $10.44 · 10.3%

The dashed line is FY25 filed $2.56, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Halozyme Therapeutics to earn $2.57 a share in the December quarter, the average of 4 estimates. Results are expected by Feb 16, 2027. Last quarter, which ended in September, Halozyme Therapeutics earned $2.01 a share. Analysts had expected $2.30, so it came in 12.8% lower.

0
$−1.13
$2.57high $2.65
low $2.47
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 4 analysts
Expected report
Feb 16, 2027
Expected by Feb 16. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$551.4M
5 analysts, 532.2 to 568.6 in $M · 451.8 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. For the March quarter, analysts expect $2.24 a share.

Does Halozyme Therapeutics usually beat or miss?

So far we have checked 9 quarters, of which 3 came in above the estimate we held. We add a quarter to this record each time Halozyme Therapeutics reports. The next report is expected by Feb 16, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '23left out · adjusted
−12.6%
Mar '24reaction
+1.9%
−5.1%
Jun '24reaction
+4.2%
+5.9%
Sep '24reaction
+13.0%
−8.5%
Dec '24reaction
+5.0%
−1.9%
Mar '25reaction
+18.1%
+4.9%
Jun '25reaction
+2.5%
−12.3%
Sep '25reaction
+2.8%
Dec '25left out · adjusted
Mar '26left out · adjusted
+6.3%
Jun '26reaction
+20.2%
−12.8%
Sep '26reaction
−15.7%
reportsFeb 16
Dec '26
Checked so far
9 quarters
one more every report
Beat expectations
3 of 9
full details on the Earnings tab
Share price reaction
+5.8%
the average over all 9 checked quarters, one session each, timed to each release
Typical gap vs estimate
−5.1%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Halozyme Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Mar '24, Jun '24, Sep '24, Dec '24, Mar '25, Jun '25, Sep '25 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 16.3% in FY27 and EPS 19.4%. Most of it is sales: the net margin moves from 54.0% to 55.4%, and the implied share count from about 124M to 124M, so these numbers assume the count stands still.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+16.3
Net margin change+3.0
Share count change+0.1
EPS growth+19.4
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
5 analysts publish an EPS estimate for FY26 and 6 publish revenue. Coverage thins with distance: 1 EPS estimate for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
65
FY26E
64
FY27E
63
FY28E
41
FY29E
31
FY30E
The FY26 panel held 4 analysts when our record of it began on Jul 6, 2026 and holds 5 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
0.51.62.7historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 6 revenue estimates for FY26, 3 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
0.806.6612.52historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 5 EPS estimates for FY26, 1 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed1.4—2.56————as filed24.4×
FY26E2.02.0 to 2.0▲42.0%a8.668.54 to 8.79▲238.2%a1.41.10.126 · 511.1×
FY27E2.32.2 to 2.4▲16.3%10.349.51 to 11.39▲19.4%1.61.30.126 · 49.3×
FY28E2.52.3 to 2.6▲8.2%11.9611.86 to 12.10▲15.7%1.91.50.126 · 38.1×
FY29E2.22.1 to 2.3▼12.8%10.6610.14 to 11.24n/cb1.71.30.124 · 19.1×
FY30E2.02.0 to 2.1▼6.3%9.919.42 to 10.44▼7.0%1.61.20.123 · 19.7×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 5 EPS estimates for FY26, 6 for revenue. Not investment advice.

What do analysts expect Halozyme Therapeutics to earn in FY26?

Analysts expect Halozyme Therapeutics to earn $8.66 a share in FY26, the average of 5 estimates as of Nov 16, 2026.

What is Halozyme Therapeutics' earnings forecast for FY27?

The FY27 consensus for Halozyme Therapeutics is $10.34 a share from 4 analysts, with a low of $9.51 and a high of $11.39, as of Nov 16, 2026.

Have analysts raised Halozyme Therapeutics' earnings estimates?

Halozyme Therapeutics' FY26 EPS consensus rose 9.0% in 90 days, from $7.94 to $8.66, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.